Humans ; Critical Illness/therapy* ; Critical Care

Critical Illness ; therapy ; Fluid Therapy ; Humans

Critical Illness ; therapy ; Humans ; Nutritional Support

No abstract available.
Critical Illness ; Humans ; Renal Replacement Therapy ; Vancomycin

Critical Illness ; Humans ; Pancreatitis, Acute Necrotizing ; diagnosis ; surgery ; therapy

In recent years, it has been realized that intestinal function plays an increasingly important role in the treatment of critically ill patients. Awareness of intestinal dysfunction becomes more and more important. Enteral nutrition is an effective method for the recovery of intestinal function, and enteral nutrition is closely related to reliable administration route. Percutaneous endoscopic gastrostomy(PEG) is a minimally invasive, simple, safe and effective enteral nutrition route.
Critical Illness ; Enteral Nutrition ; Humans ; Intestinal Diseases ; therapy

COVID-19/therapy* ; Consensus ; Critical Illness ; Humans ; SARS-CoV-2

Child ; Consensus ; Critical Illness/therapy* ; Extracorporeal Membrane Oxygenation ; Humans

Critically ill and injured patients admitted in the intensive care unit have a range of diseases with various severities. Their conditions should be assessed and the patients should receive specialized nutrition therapy depending on their condition. Like general intensive care, nutrition therapy is upgraded every few years with revised information to provide more idealized nutrition support. The main guidelines in this review are from the Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). Their previous 2009 guidelines were revised and published in 2016. This review summarizes the 2016 SCCM/ASPEN guidelines focusing on the changes from the previous 2009 guidelines.
Critical Care ; Critical Illness* ; Enteral Nutrition ; Humans ; Intensive Care Units ; Nutrition Therapy ; Nutritional Support*

Carbapenem-resistant Acinetobacter species are increasingly recognized as major nosocomial pathogens, especially in patients with critical illnesses or in intensive care. The ability of these organisms to accumulate diverse mechanisms of resistance limits the available therapeutic agents, makes the infection difficult to treat, and is associated with a greater risk of death. In this review, we provide an update on the epidemiology, resistance mechanisms, infection control measures, treatment, and outcomes of carbapenem-resistant Acinetobacter infections.
Acinetobacter ; Acinetobacter baumannii ; Acinetobacter Infections ; Colistin ; Critical Illness ; Drug Therapy ; Epidemiology ; Humans ; Infection Control ; Critical Care